hydroxychloroquine has been researched along with Pigmentary Retinopathy in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study whether the ERG and other clinical findings help to distinguish between advanced hydroxychloroquine (HCQ) retinopathy and pericentral or diffuse retinitis pigmentosa (RP) with similar fundus appearance." | 7.85 | ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. ( Marmor, MF; Nair, AA, 2017) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 7.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "Analysis of all published cases and Food and Drug Administration (FDA) reports of retinopathy attributed to hydroxychloroquine sulfate (Plaquenil) does not reveal any evidence of permanent visual field scotoma occurring when the daily dose is related to body weight and does not exceed 6." | 4.78 | Ocular safety of hydroxychloroquine sulfate (Plaquenil). ( Bernstein, HN, 1992) |
| "To study whether the ERG and other clinical findings help to distinguish between advanced hydroxychloroquine (HCQ) retinopathy and pericentral or diffuse retinitis pigmentosa (RP) with similar fundus appearance." | 3.85 | ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. ( Marmor, MF; Nair, AA, 2017) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 3.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| " Differential diagnoses include Leber's congenital amaurosis, central gyrate atrophy, central areolar choroidal sclerosis, progressive cone-rod dystrophy, syphilitic retinopathy, retinal toxicity from phenothiazine use, and chloroquine/hydroxychloroquine retinopathy." | 3.70 | Retinitis pigmentosa inversa. ( Anderson, SF; Ferrucci, S; Townsend, JC, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ahuja, P | 1 |
| Sharifi, A | 1 |
| Pakravan, M | 1 |
| Schefler, AC | 1 |
| Lee, AG | 1 |
| Liu, PK | 1 |
| Ryu, J | 1 |
| Yeh, LK | 1 |
| Chen, KJ | 1 |
| Tsang, SH | 1 |
| Liu, L | 1 |
| Wang, NK | 1 |
| Nair, AA | 1 |
| Marmor, MF | 1 |
| Ferrucci, S | 1 |
| Anderson, SF | 1 |
| Townsend, JC | 1 |
| Klinger, G | 1 |
| Morad, Y | 1 |
| Westall, CA | 1 |
| Laskin, C | 1 |
| Spitzer, KA | 1 |
| Koren, G | 1 |
| Ito, S | 1 |
| Buncic, RJ | 1 |
| Desatnik, H | 1 |
| Ashkenazi, I | 1 |
| Regenbogen, L | 1 |
| Bernstein, HN | 1 |
1 review available for hydroxychloroquine and Pigmentary Retinopathy
| Article | Year |
|---|---|
Ocular safety of hydroxychloroquine sulfate (Plaquenil).
Topics: Body Weight; Humans; Hydroxychloroquine; Retinitis Pigmentosa; Risk Factors | 1992 |
6 other studies available for hydroxychloroquine and Pigmentary Retinopathy
| Article | Year |
|---|---|
Hydroxychloroquine toxicity unmasking an occult retinitis pigmentosa carrier.
Topics: Humans; Hydroxychloroquine; Mutation; Retinitis Pigmentosa | 2023 |
A novel KCNV2 mutation in a patient taking hydroxychloroquine associated with cone dystrophy with supernormal rod response.
Topics: Adult; Antirheumatic Agents; Consanguinity; Electroretinography; Female; Frameshift Mutation; Geneti | 2021 |
ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa.
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Electroretinography; Enzyme Inhibitors; Fem | 2017 |
Retinitis pigmentosa inversa.
Topics: Adult; Atrophy; Blindness; Chloroquine; Diagnosis, Differential; Follow-Up Studies; Humans; Hydroxyc | 1998 |
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.
Topics: Antirheumatic Agents; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infa | 2001 |
Retinitis pigmentosa and discoid lupus erythematosus.
Topics: Adult; Electroretinography; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; | 1992 |